Results 291 to 300 of about 166,279 (314)

Molecular mechanism of action and pharmacokinetic properties of methotrexate

Molecular Biology Reports, 2020
V Maksimovic, Hani Al-Salami, Momir Mikov   +2 more
exaly  

Methotrexate

1999
openaire   +2 more sources

Methotrexate mechanism in treatment of rheumatoid arthritis

Joint Bone Spine, 2019
Benjamin Friedman, Bruce N Cronstein
exaly  

Comparison of methotrexate monotherapy with a combination of methotrexate and etanercept in active, early, moderate to severe rheumatoid arthritis (COMET): a randomised, double-blind, parallel treatment trial

Lancet, The, 2008
Paul Emery, Patrick Durez, Deborah Robertson   +2 more
exaly  

Efficacy and safety of tofacitinib monotherapy, tofacitinib with methotrexate, and adalimumab with methotrexate in patients with rheumatoid arthritis (ORAL Strategy): a phase 3b/4, double-blind, head-to-head, randomised controlled trial

Lancet, The, 2017
Eduardo F Mysler, Ryan Demasi, Koshika Soma   +2 more
exaly  

Adjustment of therapy in rheumatoid arthritis on the basis of achievement of stable low disease activity with adalimumab plus methotrexate or methotrexate alone: the randomised controlled OPTIMA trial

Lancet, The, 2014
Josef S Smolen, Paul Emery, Roy Fleischmann   +2 more
exaly  

Clinical and radiological characteristics of methotrexate-induced acute encephalopathy in pediatric patients with cancer

Annals of Oncology, 2008
C-H Pui
exaly  

Infliximab (chimeric anti-tumour necrosis factor α monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial

Lancet, The, 1999
R Maini, E William St Clair, Daniel Fürst   +2 more
exaly  

Oral methotrexate

Digestive Diseases and Sciences, 1986
J R, Taylor, K M, Halprin, E R, Schiff
openaire   +2 more sources

Understanding and Managing Methotrexate Nephrotoxicity

Oncologist, 2006
Brigitte C Widemann, Peter C Adamson, Widemann Brigitte C   +2 more
exaly